CTLA4 and sarcoma: Radiotherapy and chemotherapy for pleomorphic sarcoma are recommended as adjuvant therapies, and immunotherapy such as ipilimumab (anti-CTLA4), nivolumab (anti-PD1), and pembrolizumab (anti-PD1) are the current treatment modalities for this type of sarcoma; our patient did not undergo immunotherapy.